Black patients diagnosed with metastatic non-small cell lung cancer since 2017 were less likely than White patients to be tested for biomarkers that can guide treatment, according to a study of 64,000 medical records led by Debora Bruno of Case Western Reserve University (above).
Black patients were less likely to ever undergo throughout their diagnosis comprehensive genomic testing using the latest generation sequencing technology, which could reduce their opportunities for new therapies and for enrollment in clinical trials.
- See “Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment,” a video on the American Society of Clinical Oncology website (2021)
- See the abstract of the scientific paper “Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States” by Debora S Bruno et al (June, 2022)